Indivior (NASDAQ:INDV) Upgraded to Strong-Buy at Barclays

Indivior (NASDAQ:INDV) was upgraded by equities research analysts at Barclays to a “strong-buy” rating in a research note issued to investors on Thursday,Zacks.com reports.

Other equities analysts also recently issued research reports about the stock. Zacks Research upgraded shares of Indivior from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 16th. Weiss Ratings cut Indivior from a “hold (c+)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $40.29.

Indivior Stock Up 0.9%

Shares of NASDAQ:INDV opened at $38.28 on Thursday. The firm’s 50 day moving average price is $36.06 and its 200 day moving average price is $34.44. The stock has a market cap of $4.67 billion, a price-to-earnings ratio of 19.63 and a beta of 0.88. Indivior has a fifty-two week low of $13.45 and a fifty-two week high of $41.00.

Indivior (NASDAQ:INDV) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $0.96 EPS for the quarter. Indivior had a net margin of 19.44% and a negative return on equity of 219.26%. The company had revenue of $317.00 million during the quarter. On average, equities analysts anticipate that Indivior will post 4.05 EPS for the current year.

Insider Activity at Indivior

In related news, CFO Ryan Preblick sold 36,000 shares of Indivior stock in a transaction on Monday, June 8th. The shares were sold at an average price of $37.70, for a total transaction of $1,357,200.00. Following the sale, the chief financial officer directly owned 284,751 shares in the company, valued at $10,735,112.70. This trade represents a 11.22% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.74% of the stock is owned by company insiders.

Hedge Funds Weigh In On Indivior

Hedge funds have recently made changes to their positions in the company. Quarry LP purchased a new stake in shares of Indivior in the 3rd quarter valued at about $26,000. Raymond James Financial Inc. purchased a new position in Indivior during the 2nd quarter worth approximately $26,000. Salomon & Ludwin LLC acquired a new position in Indivior during the fourth quarter worth approximately $30,000. Harbor Capital Advisors Inc. increased its position in Indivior by 309.9% during the fourth quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock worth $37,000 after buying an additional 781 shares during the period. Finally, Caitong International Asset Management Co. Ltd lifted its stake in Indivior by 72.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock valued at $39,000 after buying an additional 460 shares during the last quarter. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.